Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'

Br J Clin Pharmacol. 2023 Aug;89(8):2639-2641. doi: 10.1111/bcp.15746. Epub 2023 Apr 27.
No abstract available

Keywords: IL-23 inhibitors; monoclonal antibodies; pharmacovigilance; psoriasis; risankizumab; stroke; systematic review.

Publication types

  • Letter
  • Kommentar

MeSH terms

  • Adverse Drug Reaction Reporting Systems
  • Antibodies, Monoclonal*
  • Drug-Related Side Effects and Adverse Reactions* / diagnosis
  • Drug-Related Side Effects and Adverse Reactions* / epidemiology
  • Humans
  • Pharmacovigilance
  • United States / epidemiology
  • United States Food and Drug Administration

Substances

  • risankizumab
  • Antibodies, Monoclonal